Standard BioTools sells SomaScan to Illumina, refocuses on cytometry amid losses

Snapshot - Standard BioTools Inc. (NASDAQ: FLDM)

What's happening inside the company
* Management has classified the SomaScan (aptamer/proteomics) business as held‑for‑sale and discontinued operations after signing a Stock Purchase Agreement with Illumina on June 22, 2025 (up to $425.0M cash consideration: $350.0M upfront + up to $75.0M earnouts).
* Company is refocusing on its retained mass cytometry and microfluidics businesses; it has implemented workforce reductions and other restructuring initiatives to lower costs.
* Reporting was consolidated to a single operating segment (multi‑omics company) and the SomaScan assets/liabilities and results have been presented as held‑for‑sale / discontinued operations.

Key financial facts & statistics (Q2 2025 and 6 months ended Jun 30, 2025)
* Total revenue - Q2: $21,762k vs Q2 2024 $22,492k (‑3%); 6M: $41,984k vs $44,145k (‑5%).
* Product revenue (Q2): $15,673k (Instruments $5,215k; Consumables $10,458k). Consumables +18% YoY in Q2; instruments down 26% YoY in Q2.
* Services & other revenue (Q2): $6,089k (‑8% YoY).
* Gross profit (Q2): $10,628k; gross margin 48.8% vs 46.1% (Q2 2024) - margin improved despite lower revenue.
* Operating expenses (Q2): R&D $6,222k, SG&A $28,105k, Restructuring $1,727k, Transaction & integration $271k; total operating expenses $36,325k.
* Loss from continuing operations (Q2): $(25,697)k (improved vs $(30,261)k in Q2 2024).
* Loss from discontinued operations (Q2): $(15,786)k (SomaScan business).
* Net loss (Q2): $(33,459)k; basic/diluted net loss per share: $(0.09) (Q2).
* Six months net loss: $(59,492)k (continuing $(41,043)k; discontinued $(18,449)k).
* Balance sheet (June 30, 2025): Total assets $556,965k; Total liabilities $132,430k; Stockholders' equity $424,535k; Accumulated deficit $(1,245,143)k.
* Liquidity: Cash & cash equivalents $158,617k; Short‑term investments $78,468k - combined $237,085k; Cash, cash equivalents and restricted cash at period end per cash flow section $161,204k.
* Assets held for sale (SomaScan): $223,089k (includes goodwill $111,924k allocated to the discontinued business).
* Cash flow (6 months): Net cash used in operating activities $(50,951)k; Net cash provided by investing activities $42,130k; Ending cash & restricted cash $161,204k.

Positive aspects (income statement and company actions)
* Gross margin improved to 48.8% in Q2 (from 46.1%), helped by favorable product mix (consumables growth).
* Consumables revenue growth (+18% YoY Q2) supports recurring revenue potential from installed base.
* Operating expense reduction vs prior periods on several fronts: R&D down 14% in Q2 and total operating expenses down 11% in Q2 (management is cutting long‑horizon R&D and completing prior restructuring).
* Interest expense materially lower following prior debt repayments; fewer financing costs.
* Sale of SomaScan to Illumina (if closed) would bring large upfront cash and recurring royalty/licensing streams - meaningful de‑risking of balance sheet and potential funding for core businesses.

Negative aspects (income statement and risks)
* Continued material net losses: Q2 net loss $(33.5M); 6M $(59.5M); accumulated deficit $(1,245.1M) - profitability not yet achieved.
* Operating cash burn remains significant: $(50.95M) used in operations in first half of 2025; cash runway depends on transaction proceeds and ability to cut costs.
* SG&A rose 13% YoY in Q2 to $28.1M - classified "stranded" costs after SomaScan reclassification; that pressure could persist until cost base is fully realigned.
* Discontinued operations still produced losses (Q2 $(15.8M)) and require transaction closing to stop further drag; deal subject to regulatory/HSR clearance and other closing conditions.
* Large goodwill (100% allocated to discontinued ops) and reliance on the Illumina transaction to realize value - if the deal is delayed or fails, the company faces uncertainty and potential asset‑value mismatch.
* Revenue decline year‑over‑year (Q2 down 3%; 6M down 5%) - instrument sales weakness (CyTOF XT) and services softness highlight demand/VS timing risk.
* Ongoing litigation and contingent matters (stockholder/chancery actions and Palamedrix dispute) create legal exposure and management distraction.

What to watch next (near term catalysts & risks)
* Progress and timing of the Illumina transaction closing (expected in H1 2026; reverse termination fee $14.5M if terminated under certain circumstances).
* Post‑sale operating cadence: how quickly stranded SG&A and corporate overhead are reduced and how management redeploys proceeds.
* Quarterly operating cash burn and whether disposals/earnouts materially strengthen liquidity.
* Consumables adoption and installed base trends - recurring consumables revenue is the core growth lever.
* Any material legal settlement or adverse ruling from ongoing litigation (recent court activity noted).

Bottom line: Standard BioTools (NASDAQ: FLDM) is actively reshaping itself by divesting the SomaScan proteomics business to Illumina and cutting costs, which improves near‑term margins and liquidity prospects if the deal closes. However, the company remains loss‑making, with meaningful operating cash burn, stranded SG&A pressures and dependency on the Illumina transaction and its earnouts to materially improve the balance sheet. Investors should track the transaction closing, cash flow trends, and management's ability to permanently lower SG&A and re‑grow consumables revenue from the retained instrument base.